home / stock / th:cc / th:cc news


TH:CC News and Press, Theratechnologies Inc. From 12/13/23

Stock Information

Company Name: Theratechnologies Inc.
Stock Symbol: TH:CC
Market: TSXC
Website: theratech.com

Menu

TH:CC TH:CC Quote TH:CC Short TH:CC News TH:CC Articles TH:CC Message Board
Get TH:CC Alerts

News, Short Squeeze, Breakout and More Instantly...

TH:CC - Theratechnologies Announces FDA Approval of Trogarzo® 90-Second Intravenous (IV) Push Loading Dose

Updated label means new Trogarzo ® patients no longer require initiation of treatment by 30-minute infusion Complete IV push method enables easier and more convenient administration of Trogarzo ® for heavily treatment-experienced adults with HIV M...

TH:CC - Theratechnologies Receives 2023 CQDM ADRIQ RSRI Innovation Award

MONTREAL, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of the 2023...

TH:CC - Theratechnologies Announces Closing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement

MONTREAL, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed i...

TH:CC - Theratechnologies Announces Pricing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement

Common shares priced at US$1.00 per share MONTREAL, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative...

TH:CC - Theratechnologies Announces Proposed Public Offering of Common Shares and Concurrent Private Placement

This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. MONTREAL, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc...

TH:CC - Theratechnologies Announces Operational Update

MONTREAL, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced further changes to ...

TH:CC - Theratechnologies' Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV

Data presented at AMCP Nexus 2023 highlight implications for U.S. payers based on cost-effectiveness and improved outcomes MONTREAL, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biop...

TH:CC - Theratechnologies Announces Finalization of Amendments to Some of the Terms and Conditions of its Credit Agreement with Marathon

- Revised the Minimum Liquidity Covenant for All Times Following October 31, 2023 to be Between US$15 Million and US$20 Million - Minimum Quarterly Revenue Covenant Replaced with Minimum Adjusted EBITDA Covenant - Deleted Prohibition Against Having a Going Concern Note in the Op...

TH:CC - Theratechnologies Presents Data at ID Week Showing Tesamorelin Reduces Visceral Adipose Tissue (VAT) and Liver Fat in People with HIV on Integrase Inhibitors (INSTIs)

Significant reduction in INSTI-associated VAT accumulation with tesamorelin contrasts with VAT increase in patients taking placebo VAT accumulation observed after 12 months on INSTI-containing regimens, even in the absence of significant weight or body mass index changes R...

TH:CC - Theratechnologies Announces Results from Trogarzo® (Ibalizumab-uiyk) Intramuscular Administration Study

This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. MONTREAL, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Theratechnologies I...

Previous 10 Next 10